Oral versus intravenous tranexamic acid in enhanced-recovery primary total hip and knee replacement: Results of 3000 PROCEDURES

Bone and Joint Journal

Volumn 95 B, Issue 11, 2013, Pages 1556-1561

  Irwin, A ^a   Khan, S K ^a   Jameson, S S ^a   Tate, R C ^a   Copeland, C ^a   Reed, M R ^a  

^a WANSBECK GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TRANEXAMIC ACID;

ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HOSPITAL READMISSION; HUMAN; LENGTH OF STAY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PRIORITY JOURNAL; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT;

EID: 84888311746     PISSN: None     EISSN: 20494408     Source Type: Journal    
DOI: 10.1302/0301-620X.95B11.31055     Document Type: Article

References (24)

1. Hamer AJ, Dobson PMS, Earnshaw PH, Knowles S, Newman JH. British Orthopaedic Association: blood conservation in elective orthopaedic surgery, 2005. http://www.transfusionguidelines.org.uk/docs/pdfs/bbt-03- boabloodconservation1. pdf (date last accessed 3 July 2013).
2. Sukeik M, Alshryda S, Haddad FS, Mason JM. Systematic review and metaanalysis of the use of tranexamic acid in total hip replacement. J Bone Joint Surg [Br] 2011;93-B: 39-46.
3. Rajesparan K, Biant LC, Ahmad M, Field RE. The effect of an intravenous bolus of tranexamic acid on blood loss in total hip replacement. J Bone Joint Surg [Br] 2009;91-B: 776-783.
4. Alshryda S, Sarda P, Sukeik M, et al. Tranexamic acid in total knee replacement: a systematic review and meta-analysis. J Bone Joint Surg [Br] 2011;93-B: 1577-1585.
5. Cid J, Lozano M. Tranexamic acid reduces allogeneic red cell transfusions in patients undergoing total knee arthroplasty: results of a meta-analysis of randomized controlled trials. Transfusion 2005;45: 1302-1307.
6. Zohar E, Ellis M, Ifrach N, et al. The postoperative blood-sparing efficacy of oral versus intravenous tranexamic acid after total knee replacement. Anesth Analg 2004;99: 1679-1683.
7. Malviya A, Martin K, Harper I, et al. Enhanced recovery program for hip and knee replacement reduces death rate. Acta Orthop 2011;82: 577-581.
8. Husted H, Solgaard S, Hansen TB, Søballe K, Kehlet H. Care principles at four fast-track arthroplasty departments in Denmark. Dan Med Bull 2010;57:A4166.
9. Radia H. NHS. Shortage of tranexamic acid injection (Cyklokapron injection), 2010. http://www.medicinesresources.nhs.uk/en/Communities/NHS/SPS-E- and-SE-England/ Medicines-Information/Discontinuation-Supply-Shortage-Memos/ Shortage-oftranexamic- acid-injection-Cyklokapron-injection/ (date last accessed 11 July 2013).
10. Dripps RD. New classification of physical status. Anesthesiol 1963;24:111.
11. Pilbrant A, Schannong M, Vessman J. Pharmacokinetics and bioavailability of tranexamic acid. Eur J Clin Pharmacol 1981;20: 65-72.
12. No authors listed. Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults. NICE technology appraisal guidance 170, 2009. http://www.nice.org.uk/nicemedia/pdf/ TA170Guidance.pdf (date last accessed 15 Aug 2013).
13. No authors listed. Venous thromboembolism: reducing the risk. Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital. NICE clinical guideline http://www.nice.org. uk/ nicemedia/pdf/CG92NICEGUIDELINEPDF.pdf (date last accessed 15 Aug 2013).
14. Jensen CD, Steval A, Partington PF, Reed MR, Muller SD. Return to theatre following total hip and knee replacement, before and after the introduction of rivaroxaban: a retrospective cohort study. J Bone Joint Surg [Br] 2011;93-B: 91-95.
15. Sprowson A, Symes T, Khan SK, Oswald T, Reed MR. Changing antibiotic prophylaxis for primary joint arthroplasty affects postoperative complication rates and bacterial spectrum. Surgeon 2013;11: 20-24.
16. No authors listed. Department of Health. Health Service Circular. Better blood transfusion: safe and appropriate use of blood, 2007 (HSC 2007/001). http:// www.transfusionguidelines.org.uk/docs/pdfs/nbtc-bbt-hsc-07.pdf (date last accessed 11 July 2013).
17. No authors listed. Public Health England. Protocol for the surveillance of surgical site infection. Version 6. http://www.hpa.org.uk/webc/HPAwebFile/ HPAweb-C/ 1194947388966 (date last accessed 11 July 2013).
18. Bradshaw AR, Monoghan J, Campbell D. Oral tranexamic acid reduces blood loss in total knee replacement arthroplasty. Curr Orthop Pract 2012;23: 209-212.
19. Tanaka N, Sakahashi H, Sato E, et al. Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee. J Bone Joint Surg [Br] 2001;83-B: 702-705.
20. Eriksson O, Kjellman H, Pilbrant A, Schannong M. Pharmacokinetics of tranexamic acid after intravenous administration to normal volunteers. Eur J Clin Pharmacol 1974;7: 375-380.
21. Andersson L, Nilsoon IM, Colleen S, Granstrand B, Melander B. Role of urokinase and tissue activator in sustaining bleeding and the management thereof with EACA and AMCA. Ann N Y Acad Sci 1968;146: 642-658.
22. Irisson E, Hémon Y, Pauly V, et al. Tranexamic acid reduces blood loss and financial cost in primary total hip and knee replacement surgery. Orthop Traumatol Surg Res 2012;98: 477-483.
23. Lozano M, Basora M, Peidro L, et al. Effectiveness and safety of tranexamic acid administration during total knee arthroplasty. Vox Sang 2008;95: 39-44.
24. No authors listed. NHS Blood and Transplant. Strategic Plan 2013 - 2018. http:// www.nhsbt.nhs.uk/strategicplan/download/nhsbt-strategic-plan-201318.pdf (date last accessed 11 July 2013).